Patient characteristics
| Patient code . | Starting WBC (× 109/L) . | Starting CD34 (%) . | CD34 enrichment (%) . |
|---|---|---|---|
| CML 1 | 181 | 0.5 | 46 |
| CML 2 | 234 | 5.5 | 78 |
| CML 3 | 518 | 5.3 | 98 |
| CML 4 | 741 | 3.4 | 99 |
| CML 5 | 206 | 19 | 96 |
| CML 6 | 410 | 3.3 | 58 |
| CML 7 | 701 | 14.4 | 85 |
| Patient code . | Starting WBC (× 109/L) . | Starting CD34 (%) . | CD34 enrichment (%) . |
|---|---|---|---|
| CML 1 | 181 | 0.5 | 46 |
| CML 2 | 234 | 5.5 | 78 |
| CML 3 | 518 | 5.3 | 98 |
| CML 4 | 741 | 3.4 | 99 |
| CML 5 | 206 | 19 | 96 |
| CML 6 | 410 | 3.3 | 58 |
| CML 7 | 701 | 14.4 | 85 |
All patient samples were collected at diagnosis before therapy. All patients had chronic-phase CML and t(9;22) and were BCR-ABL+.